Autologous T cell activation fosters venetoclax resistance in CLL: rationale for a combined therapy with the BCR kinase inhibitor GS-9973 and anti-CD20 mAbs.

ALMEJUN MARIA BELÉN; VERGARA-RUBIO, MARICEF; CABREJO, MARÍA; CUSTIDIANO, MARÍA DEL ROSARIO; BORGE MERCEDES; COLADO ANA; PODAZA ENRIQUE; FERNANDEZ GRECCO HORACIO; SANCHEZ AVALOS JULIO; GIORDANO MIRTA; ELIAS ESTEBAN ENRIQUE; CORDINI, GREGORIO; RISNIK DENISE; BEZARES RAIMUNDO FERNANDO; GARATE GONZALO MARTÍN; GAMBERALE, ROMINA

Workshop; 3rd IBAM-CLL; 2018

AutologousT cell activation fosters venetoclax resistance in CLL: rationale for acombined therapy with the BCR kinase inhibitor GS-9973 and anti-CD20 mAbs. Elías E; Almejún M; Colado A;Cordini G; Vergara-Rubio M; Podaza E; Risnik D; Cabrejo M; Fernandez-Grecco H;Bezares R; Custidiano M; Sanchez-Ávalos J; Vicente U; Garate G; Borge M;Giordano M; Gamberale R. 3er Congreso Iberoamericano deLeucemia Linfocítica Crónica 2018 (IBAM 2018), Buenos Aires, Argentina. Agosto2018. Número especial de la revista de la sociedad argentina de hematología(SAH), volumen 22, Agosto 2018